Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary

Akari Therapeutics

13/08/2026 21:50

Akari Therapeutics PLC AKTX.OQ reported a quarterly adjusted loss of $2.68​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported breakeven earnings per share.  The mean expectation of three analysts for the quarter was for a loss of $1.28 per share. Wall Street expected results to range from $-2.80 tozero cents per share.
Reported revenue was zero​; analysts expected zero. 
Akari Therapeutics PLC's reported EPS for the quarter was a loss of $2.68​.
The company reported a quarterly loss of $4.81 million.
Akari Therapeutics PLC shares had fallen by 29.9% this quarter and lost 37.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 8.4% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Akari Therapeutics PLC is $30.00, about 76.1% above its last closing price of $7.18
This summary was machine generated from LSEG data August 13 at 08:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.28
-2.68
Missed
Mar. 31 2026 
-1.38
-1.57
Missed
Dec. 31 2025 
-1.50
0.00
Beat
Sep. 30 2025 
-3.07
0.00
Beat